Celerion’s Post

Vamorolone, a Potential Duchenne Muscular Dystrophy Therapy, Undergoes Priority Review in China Sperogenix Therapeutics has applied for approval of vamorolone for the treatment of Duchenne Muscular Dystrophy (DMD) in China. The filing has been accepted by the NMPA, and a decision is expected in the first quarter of next year. The New Drug Application is supported by comprehensive data that has already led to vamorolone's approval in the US, EU, and UK. Sperogenix holds the exclusive rights to develop and market vamorolone in China under a license agreement with Santhera. The potential approval of vamorolone in China would be a significant step forward in treating DMD. For more details please click the link! https://lnkd.in/d5JJxrpX #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

Cardiac liability of new therapeutic agents needs to be thoroughly investigated during a preclinical drug discovery program. Towards this, CRL now offers a comprehensive assessment of cardiac liability for novel compounds using established CiPA Ion channel panel, on Automated Patch Clamp system. For more details contact our client service https://lnkd.in/eGbNJsNC or connect with our specialists Stefano Stabilini and Amit Kumar Chouhan, PhD #drugdevelopment #CharlesRiver #Cardiotoxicity #pharmacology #drugdiscovery #ionchannels Follow us at Discovery | Charles River

Radiopharmaceuticals have proven to be effective agents since they can be successfully applied for both diagnostics and therapy. Radionuclide drug conjugates (RDCs) combine a radioactive compound, a tailored-targeting molecule for specific receptors enriched on diseased cells, and a linker for stable attachment. By attacking only cancerous cells, this approach enables more effective radiation delivery and significantly reduces side effects. WuXi AppTec has developed a comprehensive workflow for radiopharmaceutical discovery and development, from target selection and ligand ID to stability testing and in vivo efficacy/safety assessment. Curious to learn more? Watch the video ⬇️ https://lnkd.in/e_XeBg-C #DrugDiscovery #RDC #Radionuclide #Radiopharmaceutical

I am thrilled to announce that my book chapter titled "Kisspeptin-1 Signaling Pathway in Infertility: Exploring the Molecular Pathways and Therapeutic Implications for Reproductive Dysfunction" has been accepted for publication in the edited book titled "Recent Advances in Pharmaceutical Sciences (Volume 13)."

In a recent contribution to European Pharmaceutical Manufacturer, SCTbio details the potential of leukapheresis #celltherapy to treat or even cure rare diseases, as well as how effective apheresis cell collection is needed to realise this potential. As experts in the field, with over 150 active apheresis cell collection centres, SCTbio is well placed to outline the key considerations for effective #apheresis cell collection: https://lnkd.in/eVpnzqAh The article was also written with valuable input from our partners Cyto-Care – specialists in providing advanced solutions for cell therapy and regenerative medicine. Through a collaborative and beneficial partnership, Cyto-care.eu and SCTbio will provide a reliable and accessible platform for collecting, characterizing, cryopreserving, and transporting #leukapheresis samples. Markus Dettke Klaus Fischer Miroslav Hlaučo #CGT

MK-1084: A Macrocyclic KRAS(G12C) Inhibitor from Merck | https://lnkd.in/gm6vhQYw Merck recently disclosed the medicinal chemistry story of their clinical KRAS(G12C) compound at the ACS Spring 2024 meeting. Using Amgen’s sotorasib as a starting point, the Merck team utilized a structurally guided macrocyclization approach to maximize potency and MetID studies to inform PK optimization leading to MK-1084. Notably, this covalent macrocyclic KRAS(G12C) inhibitor is showing promise in the clinic in combination with Merck’s cornerstone PD-1 inhibitor pembrolizumab (Keytruda™). Check out the story on Drug Hunter | https://lnkd.in/gm6vhQYw You can also find our round-up of the 12 KRAS(G12C) clinical molecules to know | https://lnkd.in/g35PiZGA

Nomeculature Series #Autonomic_Nervous_System 3 #Mirabegron Mira: came from miracle due to the efficacy of mirabegron in the treatment of over active bladder. Begron: refers to its mechanism of action as a beta-3 adrenergic receptor agonist. Join me and Atheer Alrawashdeh on our enlightening adventure as we explore the world of #drugnaming #pharmacology #pharmacy #pharmacist #nomeculature

a good target for total synthesis!

Join our upcoming webinar to learn about recent advancements in peptide drug discovery, including the evolution of mRNA display and peptide DNA-encoded library (DEL) technology for hit generation and selection, as well as novel cyclization techniques and their combinations for peptide conformational rigidity. This webinar will provide a comprehensive perspective on strategies that are crucial for achieving the desired binding affinity and efficacy for developing potent and orally available peptide drugs. Don’t miss your chance to ask questions to our experts! Register Today! https://lnkd.in/edDidzQ5 #Peptide #DrugDiscovery #mRNA #DELTechnology #PeptideTherapeutics #OralPeptideDrugs #DMPK